Additionally, we review the role of pharmaceutical inhibitors for MLCK or ROCK, suggesting potential therapeutic targeting of MLCK- or ROCK-associated regulation of AJC in gastrointestinal disorders that compromise intestinal epithelial integrity. The gene discussed is MYLK2; the disease is digestive system disorder.